CN116059347A - 使用her3抗原结合分子治疗和预防癌症 - Google Patents

使用her3抗原结合分子治疗和预防癌症 Download PDF

Info

Publication number
CN116059347A
CN116059347A CN202211117480.0A CN202211117480A CN116059347A CN 116059347 A CN116059347 A CN 116059347A CN 202211117480 A CN202211117480 A CN 202211117480A CN 116059347 A CN116059347 A CN 116059347A
Authority
CN
China
Prior art keywords
amino acid
acid sequence
seq
region
her3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202211117480.0A
Other languages
English (en)
Chinese (zh)
Inventor
J·D·博伊德-柯克普
关思宇
P·英格拉姆
K·帕兹基维奇
V·桑塞农
D·萨克
吴志浩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hummingbird Biotechnology Pte Ltd
Original Assignee
Hummingbird Biotechnology Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hummingbird Biotechnology Pte Ltd filed Critical Hummingbird Biotechnology Pte Ltd
Publication of CN116059347A publication Critical patent/CN116059347A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202211117480.0A 2019-09-11 2020-09-10 使用her3抗原结合分子治疗和预防癌症 Pending CN116059347A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1913079.8A GB201913079D0 (en) 2019-09-11 2019-09-11 Treatment and prevention of cancer using her3 antigen-binding molecules
GB1913079.8 2019-09-11
PCT/EP2020/075319 WO2021048274A1 (en) 2019-09-11 2020-09-10 Treatment and prevention of cancer using her3 antigen-binding molecules
CN202080009114.6A CN113347994B (zh) 2019-09-11 2020-09-10 使用her3抗原结合分子治疗和预防癌症

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202080009114.6A Division CN113347994B (zh) 2019-09-11 2020-09-10 使用her3抗原结合分子治疗和预防癌症

Publications (1)

Publication Number Publication Date
CN116059347A true CN116059347A (zh) 2023-05-05

Family

ID=68241208

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202211117480.0A Pending CN116059347A (zh) 2019-09-11 2020-09-10 使用her3抗原结合分子治疗和预防癌症
CN202080009114.6A Active CN113347994B (zh) 2019-09-11 2020-09-10 使用her3抗原结合分子治疗和预防癌症

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202080009114.6A Active CN113347994B (zh) 2019-09-11 2020-09-10 使用her3抗原结合分子治疗和预防癌症

Country Status (16)

Country Link
US (2) US11208498B2 (https=)
EP (2) EP3818086B1 (https=)
JP (2) JP7708741B2 (https=)
KR (1) KR20220086554A (https=)
CN (2) CN116059347A (https=)
AU (1) AU2020347473A1 (https=)
BR (1) BR112022004474A8 (https=)
CA (1) CA3149853A1 (https=)
DK (1) DK3818086T3 (https=)
ES (1) ES2896921T3 (https=)
GB (1) GB201913079D0 (https=)
MX (1) MX2022002977A (https=)
PL (1) PL3818086T3 (https=)
PT (1) PT3818086T (https=)
TW (1) TWI883044B (https=)
WO (1) WO2021048274A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3433273T (pt) 2016-03-25 2022-02-21 Biomunex Pharmaceuticals Moléculas de ligação a cd38 e pd-l1
SG11201809316XA (en) * 2016-04-28 2018-11-29 Biomunex Pharmaceuticals Bispecific antibodies targeting egfr and her2
KR20240125061A (ko) 2017-03-27 2024-08-19 바이오뮤넥스 파마슈티컬스 안정적인 다중특이적 항체
WO2019185164A1 (en) 2018-03-29 2019-10-03 Hummingbird Bioscience Holdings Pte. Ltd. Her3 antigen-binding molecules
CN114790462B (zh) * 2021-01-25 2023-10-31 中国医学科学院血液病医院(中国医学科学院血液学研究所) 靶向bcma的嵌合抗原受体及其应用
CN112961865B (zh) * 2021-02-22 2023-06-02 广西大学 一种利用基因编辑鸡生物反应器表达的重组曲妥珠单抗及应用
EP4304636A1 (en) * 2021-03-11 2024-01-17 Elevation Oncology, Inc. Dosage and administration of anti-erbb3 (her3) monoclonal antibodies to treat tumors associated with neuregulin 1 (nrg1) gene fusions
TW202313987A (zh) * 2021-06-03 2023-04-01 荷蘭商美勒斯公司 用於測定nrg1融合多核苷酸的液態檢體測定法
JP2024523001A (ja) * 2021-06-03 2024-06-25 メルス ナムローゼ フェンノートシャップ 新たなｎｒｇ１融合体、融合接合部及びそれらを検出するための方法
GB202108449D0 (en) 2021-06-14 2021-07-28 Hummingbird Bioscience Holdings Pte Ltd Cells expressing her3 antigen-binding molecules
US20250136712A1 (en) 2021-08-13 2025-05-01 Hummingbird Bioscience Pte. Ltd. Treatment and prevention of cancer using her3 antigen-binding molecules
JP2024536719A (ja) * 2021-09-03 2024-10-08 キャンサー・リサーチ・テクノロジー・リミテッド Ｈｅｒ３抗原結合性分子を使用したがんの処置および予防
CN116333118B (zh) * 2021-12-16 2024-04-19 徕特康(苏州)生物制药有限公司 抗表皮生长因子受体抗体及其制备方法和用途
US20240117030A1 (en) * 2022-03-03 2024-04-11 Pfizer Inc. Multispecific antibodies and uses thereof
WO2024121163A1 (en) 2022-12-06 2024-06-13 Cancer Research Technology Limited Combination of 10d1f and an androgen inhibitor for treatment and prevention of cancers
CN120417924A (zh) 2022-12-07 2025-08-01 蜂鸟生物科技私人有限公司 治疗和预防癌症的组合疗法
WO2024147097A1 (en) 2023-01-03 2024-07-11 Hummingbird Bioscience Pte. Ltd. Her3-binding antibody-drug conjugate
EP4687972A1 (en) 2023-04-06 2026-02-11 Hummingbird Bioscience Pte. Ltd. Treatment and prevention of cancer using her3 antigen-binding molecules
KR20260022498A (ko) 2023-04-14 2026-02-19 허밍버드 바이오사이언스 피티이. 엘티디. 암의 치료 및 예방을 위한 조합물
WO2025057173A2 (en) * 2023-09-14 2025-03-20 B.G. Negev Technologies And Applications Ltd. Ligand-based chimeric antigen receptors and uses thereof
WO2025056781A1 (en) 2023-09-15 2025-03-20 Hummingbird Bioscience Pte. Ltd. Treatment and prevention of cancer using her3-binding molecules

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107207594A (zh) * 2014-12-23 2017-09-26 百时美施贵宝公司 针对tigit的抗体
US20180155433A1 (en) * 2015-05-06 2018-06-07 Gamamabs Pharma Anti-human-her3 antibodies and uses thereof
CN112513095A (zh) * 2018-03-29 2021-03-16 蜂鸟生物科技控股私人有限公司 Her3抗原结合分子

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP1283053A1 (en) * 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
MY152068A (en) * 2009-03-20 2014-08-15 Genentech Inc Bispecific anti-her antibodies
EP2571901B1 (en) * 2010-05-20 2019-01-02 Ablynx N.V. Biological materials related to her3
CN104105709A (zh) * 2011-12-05 2014-10-15 诺华股份有限公司 抗her3的结构域ii的表皮生长因子受体3(her3)抗体
US20130259867A1 (en) * 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
EP2961773B1 (en) 2013-02-26 2019-03-20 Roche Glycart AG Bispecific t cell activating antigen binding molecules
WO2014182970A1 (en) * 2013-05-08 2014-11-13 Zymeworks Inc. Bispecific her2 and her3 antigen binding constructs
EP3085781A1 (en) 2013-12-19 2016-10-26 National Cancer Center Novel fusion gene as factor responsible for stomach cancer
WO2016059602A2 (en) * 2014-10-16 2016-04-21 Glaxo Group Limited Methods of treating cancer and related compositions
IL269656B2 (en) 2017-03-31 2024-06-01 Merus Nv Bispecific antibodies that bind ERBB-2 and ERBB3 for use in the treatment of cells with NRG1 fusion gene
EP3679063A4 (en) 2017-09-08 2021-06-02 The Regents of The University of Colorado, A Body Corporate COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATMENT OR PREVENTION OF HER-CONTROLLED DRUG-RESISTANT CANCER
US20190300610A1 (en) 2018-03-29 2019-10-03 Hummingbird Bioscience Pte. Ltd. Vista antigen-binding molecules

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107207594A (zh) * 2014-12-23 2017-09-26 百时美施贵宝公司 针对tigit的抗体
US20180155433A1 (en) * 2015-05-06 2018-06-07 Gamamabs Pharma Anti-human-her3 antibodies and uses thereof
CN112513095A (zh) * 2018-03-29 2021-03-16 蜂鸟生物科技控股私人有限公司 Her3抗原结合分子

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ALEXANDER DRILON等: "Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers", CANCER DISCOV, 30 June 2018 (2018-06-30), pages 686, XP055759657, DOI: 10.1158/2159-8290.CD-17-1004 *

Also Published As

Publication number Publication date
KR20220086554A (ko) 2022-06-23
TWI883044B (zh) 2025-05-11
PT3818086T (pt) 2021-10-26
JP7708741B2 (ja) 2025-07-15
PL3818086T3 (pl) 2022-03-14
US20210155712A1 (en) 2021-05-27
GB201913079D0 (en) 2019-10-23
US11208498B2 (en) 2021-12-28
CN113347994B (zh) 2022-09-23
BR112022004474A2 (pt) 2022-06-21
CA3149853A1 (en) 2021-03-18
DK3818086T3 (da) 2021-10-04
TW202123926A (zh) 2021-07-01
EP3943509A1 (en) 2022-01-26
AU2020347473A1 (en) 2022-03-31
MX2022002977A (es) 2022-07-12
BR112022004474A8 (pt) 2023-01-17
ES2896921T3 (es) 2022-02-28
JP2025143396A (ja) 2025-10-01
EP3818086B1 (en) 2021-08-04
WO2021048274A1 (en) 2021-03-18
JP2022548057A (ja) 2022-11-16
EP3818086A1 (en) 2021-05-12
US20220153870A1 (en) 2022-05-19
CN113347994A (zh) 2021-09-03

Similar Documents

Publication Publication Date Title
CN113347994B (zh) 使用her3抗原结合分子治疗和预防癌症
JP7545437B2 (ja) Ｈｅｒ３抗原結合性分子
HK40075856A (en) Her3 antigen-binding molecules
HK40052624B (en) Treatment and prevention of cancer using her3 antigen-binding molecules
HK40052624A (en) Treatment and prevention of cancer using her3 antigen-binding molecules
HK40026637B (en) Her3 antigen-binding molecules
HK40026637A (en) Her3 antigen-binding molecules

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination